Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API

Wanbury Limited has been awarded a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for its Dextromethorphan active pharmaceutical ingredient {API), antitussive (cough) medicine.

The global formulation market for Dextromethorphan is valued at USD 2,500 million for FY24, having grown by 7% over the past year. With the CEP certification, Wanbury is wellpositioned to initiate the commercial sales of this product in European markets.

Bafna Pharmaceuticals honoured with award by PHARMEXCIL

Bafna Pharmaceuticals Limited has been honoured with the prestigious All-Round Silver Star (MSME) - Export Performance Award for the Year 2022-2023 by the Pharmaceuticals Export Promotion Council of India (PHARMEXCIL), in recognition of exceptional contribution made by the Company to the Pharmaceutical Export Sector of India.